MedTrace Logo

Tw HER2 Positive Breast Cancer Productivity & Utility Study

NCT04011085 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-07-08

No results posted yet for this study

Summary

Breast cancer ranks top 4 Taiwan mortality cause in 2016 and the incidence rate has been increasing. Since advances in screening and treatment over last decades, disease-free survival in HER2 positive breast cancer improved and relapse rates decrease as well. While health-related quality of life (HRQoL) and productivity benefit is not currently formally assessed by Taiwan Health Technology Agency (HTA) in Taiwan, the value of therapy in terms of a wider societal benefit is a critical factor which is increasingly being considered as part of the overall assessment of the value of a new medicine.

Sort of productivity study in cancer is lack of in Taiwan. Referenced Roche UK team published comprehensive productivity studies1 Taiwan Epidemiology Association wants to initiate study to understand holistic value in each stage of breast cancer and quantify the value of new drug to support HTA assessment.

The data will be collected through study, and adapt to cost-effectiveness model for future reimbursement submission.

Conditions

Sponsors & Collaborators

  • Taiwan Epidemiology Association

    lead OTHER

Principal Investigators

  • Ching-Hung Lin, Ph.D · National Taiwan University Hospital

  • Liang-Chih Liu, Ph.D · China Medical University Hospital

  • Ming-Feng Hou, M.D. · Kaohsiung Medical University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-24
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04011085 on ClinicalTrials.gov